share_log

Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $22

Benzinga ·  Nov 10, 2023 09:26

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $23 to $22.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment